Prothena Future Growth

Future criteria checks 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Prothena.

Key information

23.2%

Earnings growth rate

24.8%

EPS growth rate

Biotechs earnings growth55.0%
Revenue growth rate58.8%
Future return on equityn/a
Analyst coverage

Good

Last updated09 May 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:0PT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025141-173-61N/A6
12/31/202460-210-114N/A10
12/31/202314-217-41N/A10
3/31/20201-80-59-59N/A
12/31/20191-78-54-53N/A
9/30/20191-79-62-60N/A
6/30/20191-84-86-84N/A
3/31/20191-128-16-14N/A
12/31/20181-156-30-28N/A
9/30/20181-181-47-47N/A
6/30/20181-209-32-31N/A
3/31/201827-167-126-125N/A
12/31/201728-153-135-131N/A
9/30/201727-154-136-125N/A
6/30/201728-145-156-138N/A
3/31/20171-168-148-129N/A
12/31/20161-160N/A-116N/A
9/30/20161-135N/A-102N/A
6/30/20161-115N/A-89N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0PT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0PT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0PT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0PT's revenue (58.8% per year) is forecast to grow faster than the German market (4.5% per year).

High Growth Revenue: 0PT's revenue (58.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0PT's Return on Equity is forecast to be high in 3 years time


Discover growth companies